Scott Buzby
Online Managing Editor at Healio Cardiac/Vascular Intervention
Online Managing Editor for @CardiologyToday
Articles
-
2 days ago |
healio.com | Scott Buzby
Key takeaways: In the SOUL trial, Rybelsus reduced risk for heart events by 14% in patients with diabetes and prior heart and/or kidney disease. New analyses show change in HbA1c or body weight did not impact outcomes. CHICAGO — For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related events, with consistent findings in further analyses, according to new data from the SOUL trial.
-
2 days ago |
healio.com | Scott Buzby
ACC guidance permits use of modern medications as first-line therapy for obesity• An ACC panel states modern obesity medications may be considered as first-line therapy for treatment of obesity. • Patients should not be required to ‘try and fail’ lifestyle changes first, the panel wrote. A clinical guidance from the American College of Cardiology Solution Set Oversight Committee states that pharmacotherapy may be considered as the first treatment for patients with obesity.
-
3 days ago |
healio.com | Scott Buzby
Key takeaways: Universal access to GLP-1 therapies could reduce the prevalence of obesity by up to 52% in eligible populations. Widened access is also estimated to lower global all-cause mortality. CHICAGO — Universal access to GLP-1 receptor agonists for eligible populations could reduce global obesity prevalence by half and save 37 million lives over 5 years, according to new research.
-
5 days ago |
healio.com | Scott Buzby
Key takeaways: Semaglutide improved time in glycemic range in patients with type 1 diabetes and obesity using an automated insulin delivery system. The GLP-1 also reduced body weight and maintained low hypoglycemia rates. CHICAGO — Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia compared with placebo in patients with type 1 diabetes and obesity using an automated insulin delivery system. Viral N.
-
5 days ago |
healio.com | Scott Buzby
Semaglutide may improve stroke risk vs. empagliflozin for diabetes• Semaglutide further reduced risk for stroke vs. empagliflozin as treatment for diabetes. • Dulaglutide’s impact on CV outcomes was similar vs. empagliflozin. Diabetes treatment with semaglutide was associated with significantly reduced risk for stroke compared with empagliflozin, researchers reported.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 94
- Tweets
- 187
- DMs Open
- No
RT @ACCmediacenter: According to new research, dietary sources of sodium vary by race, along with recommendations for lowering intake. @Sco…
RT @ACCmediacenter: A new study presented at #ACC25 assessed the relationship between skin pigmentation and pulse oximeter bias among criti…
RT @ACCmediacenter: Acute respiratory syncytial virus was linked to an increased incidence of CV events among older adults, according to ne…